News for Atara Biotherapeutics, Inc. (0HIY.L)

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biot

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.27% to 43,106.65 while...

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.1% on Thursday. The Dow traded up 0.08% to 43,256.69 while the NASDA...

U.S. stocks traded slightly lower this morning, with the Dow Jones index falling around 0.2% on Thursday. Following the market opening Thursday, the Dow traded...

Atara stock plummets on FDA setback for EBV drug

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

The FDA decision on Datopotamab Deruxtecan, proposed for the treatment of patients with previously treated metastatic HR-positive, HER2-negative breast cancer, is due on January 29, 2025.

**media[483102]**

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

**media[481925]**

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Wednesday. The Dow traded down 0.08% to 40,906.17 while the N...

Shares of GitLab Inc. GTLB rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter financial results and issue...

Loading... Loading... Shares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoin...

MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging...

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.35%